Innovation Pharmaceuticals Inc (IPIX)

[KMBJN]

Not having seen the PK data from the Phase I bioequivalence study, I recall that Prurisol oral bioavailability is only 25%, whereas Ziagen's is 83%:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=99927228

So, 200 mg of Prurisol gives 25% in plasma, or 50 mg.

Typical Ziagen dose is 600 mg, with 83% converted to abacavir in plasma, or close to 500 mg.

Thus Prurisol (in my crude analysis) is only 1/10th the typical Ziagen daily dose of abacavir.

Regarding the hypersensitivity reaction, perhaps CTIX rolled the dice and hoped the small dose would not lead to big problems. Perhaps they didn't do genetic screening first, and just stopped the drug on any hypersensitivity reaction, even though these can be fatal. My hospital system is very proactive with EMR and personalized medicine (especially pharmacogenomics), so our policy of automatic electronic "warning" requiring genetic testing before dispensing abacavir is probably not the norm.

Overall, the 200 mg results are very promising, and for sure room to go higher on the dosing, hopefully keeping the good side effect profile at higher doses.

Hope big pharma likes the data, and we can monetize this asset now to fund our other trials.